At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

Zsolt Farkas of Evolut on why today's longevity valuations only work if the winners spend the next decade buying everything ...

Aging Research and Drug Discovery meeting opened with a pitch for prevention and a program building the endpoints the field needs.

A Tokyo startup called TIME TRAVELER thinks the antiaging answer was sitting in the vegetable drawer all along.

Basecamp Research will train AI models on the world’s largest biological dataset and design new medicines. Most AI ...

A further $173 billion a year is real on paper – but only once three separate regulatory clocks finish running down.

One-year results for the open-chest version look promising, the company says, and a catheter-based method is now enrolling ...

Amorepacific deal puts therapeutic target discovery to work on skin aging – and Junevity sees scope for an ‘Ozempic moment’.

Ten innovations spanning diagnostics, AI, mobility, mitochondria and regenerative medicine have been recognized at a Hong Kong summit.

Younger founder Christin Glorioso on turning a six-month competition into a side-by-side trial of aging clocks.

Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same ...

What if the biggest problem with your supplements isn’t what you take, but how much actually reaches your cells? Phil Newman sits down with Dr. Christopher Shade, founder and CEO of Quicksilver ...